Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to -$15.0 million.

  • Fortress Biotech's Cash from Investing Activities was N/A to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year change of. This contributed to the annual value of -$15.0 million for FY2024, which is 613.27% down from last year.
  • As of FY2024, Fortress Biotech's Cash from Investing Activities stood at -$15.0 million, which was down 613.27% from -$2.1 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Cash from Investing Activities ranged from a high of $40.5 million in FY2021 and a low of -$22.9 million during FY2022.
  • Its 3-year average for Cash from Investing Activities is -$13.3 million, with a median of -$15.0 million in 2024.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 665.52% in 2021, then tumbled by 613.27% in 2024.
  • Over the past 5 years, Fortress Biotech's Cash from Investing Activities (Yearly) stood at -$7.2 million in 2020, then spiked by 665.52% to $40.5 million in 2021, then tumbled by 156.59% to -$22.9 million in 2022, then spiked by 90.83% to -$2.1 million in 2023, then tumbled by 613.27% to -$15.0 million in 2024.